Compare AstraZeneca plc (AZN) vs Veritone Inc (VERI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
AstraZeneca plc vs Veritone Inc — how do they compare? AstraZeneca plc trades at $158.4 (market cap $248.14B), while Veritone Inc trades at $1.49 (market cap $138.04M). The key difference: AstraZeneca plc is far larger — about 1797.6× Veritone Inc's market cap, and AstraZeneca plc pays a 2.01% dividend while Veritone Inc pays none. Which is the better fit depends on your goals.
| AZN | VERI | |
|---|---|---|
Market Cap | $248.14B | $138.04M |
Sector | Health | Technology |
52-Week High | $209.48 | $8.39 |
52-Week Low | $147.06 | $1.00 |
Enterprise Value | $275.41B | $170.07M |
Dividend Yield | 2.01% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AstraZeneca (AZN) trades at $158.48, down 2.12% amid bearish technical signals and merger speculation. The stock shows strong fundamentals with revenue growth from $54.1B in 2024 to $58.7B in 2025 and net income reaching $10.2B. Recent earnings beats and a 47.5% analyst buy rating contrast with technical indicators showing oversold conditions near key support at $155.
Investment outlook remains positive based on earnings momentum and valuation metrics (P/E 23.76), though risks include potential merger integration challenges and ongoing legal investigations. The company's robust cash flow generation and dividend payments provide shareholder value support despite near-term volatility.
Veritone (VERI) trades at $1.53, up 6.25% in 24 hours, with a bullish technical signal from moving averages and ADX indicators. The company reported revenue of $92.19M in 2025 but a net loss of $111.73M, reflecting negative profit margins and ROE. Recent news highlights partnerships with ZeroEyes and the Department of Energy, though a securities class action lawsuit was filed in July 2026 over alleged accounting issues.
The outlook is mixed: analyst consensus leans neutral with 46% buy ratings, but persistent losses and legal risks pose challenges. Upside hinges on AI partnership growth improving profitability, while downside risks include ongoing cash burn and litigation uncertainties. Investors should weigh growth potential against financial stability concerns.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About AstraZeneca plc
A merger between Astra of Sweden and Zeneca Group of the United Kingdom formed AstraZeneca in 1999. The firm sells branded drugs across several major therapeutic classes, including gastrointestinal, diabetes, cardiovascular, respiratory, cancer, and immunology. The majority of sales come from international markets with the United States representing close to one third of its sales.
Read more on AZN →About Veritone Inc
Veritone is a leading provider of enterprise AI software and solutions, centered on its proprietary AI operating system, aiWARE™. The platform orchestrates a vast ecosystem of machine learning models to transform unstructured data—such as audio, video, and text—into actionable intelligence. Serving the media, entertainment, and public sectors, Veritone is a critical infrastructure partner for organizations looking to monetize data archives and operationalize AI at scale.
Read more on VERI →
